A 38-year-old man from rural Maharashtra presents with a 3-month history of productive cough, fever, and weight loss. Chest X-ray shows a cavitary lesion in the right upper lobe. Sputum smear microscopy is positive for acid-fast bacilli (AFB). He is started on standard first-line anti-tuberculous therapy (ATT). After 2 months of treatment, repeat sputum smear remains positive despite good adherence. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient presents with **treatment failure** — defined as sputum positivity at 2 months or later despite adherence to standard first-line ATT. This is a key indicator for suspected drug-resistant tuberculosis (MDR-TB or XDR-TB). ## Management of Treatment Failure **Key Point:** Persistent sputum positivity at 2 months despite adherent first-line therapy mandates immediate investigation for drug resistance and switch to second-line regimens pending DST results. ### Diagnostic Approach 1. Perform **drug susceptibility testing (DST)** urgently to identify resistance pattern (MDR, XDR, or other) 2. Initiate **second-line ATT** empirically while awaiting DST results 3. Do NOT continue first-line drugs in a failing patient — this risks further resistance acquisition ### Second-Line Regimen (WHO/RNTCP Guidelines) Standard MDR-TB regimen includes: - Fluoroquinolone (levofloxacin or moxifloxacin) - Injectable agent (amikacin or streptomycin) - Ethionamide or prothionamide - Cycloserine or linezolid - Duration: 20 months (intensive phase 8 months + continuation phase 12 months) **High-Yield:** Treatment failure at 2 months = **presumed MDR-TB until proven otherwise**. Delay in switching to second-line therapy increases mortality and transmission risk. ## Why Other Options Are Incorrect **Continuing first-line drugs:** Allows further selection of resistant mutants and worsens prognosis. This is a critical error in TB management. **Adding ethionamide alone:** Ethionamide is a second-line drug but must be part of a complete second-line regimen, not an add-on to failing first-line therapy. **Increasing first-line drug doses:** Does not address underlying drug resistance; dose escalation is ineffective against resistant strains. **Clinical Pearl:** The definition of treatment failure in TB is sputum positivity at ≥2 months of treatment in a patient with documented good adherence. This triggers immediate DST and second-line therapy initiation.